143224-34-4|Telinavir|Butanediamide, N1-((1S,2R)-3-((((1,1-dimethylethyl)amino)carbonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (2S)-|-范德生物科技公司

Telinavir

NMR下载 COA and HPLC MSDS下载
names：
Butanediamide, N1-((1S,2R)-3-((((1,1-dimethylethyl)amino)carbonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (2S)-
CAS号：
143224-34-4
MDL Number：
MF(分子式)： C33H44N6O5 MW(分子量)： 604.752
EINECS: Reaxys Number:
Pubchem ID: Brand:BIOFOUNT

货品编码	规格	纯度	价格 (¥)	现价(¥)	特价(¥)	库存描述	数量	总计 (¥)

大包装询价提供各种包装，敬请垂询
收藏商品商品点评加入购物车立即购买

快速询价

收起

你想询价的产品

*产品名称：

CAS号：

产品编号：

需求描述：

请准确填写您的联系方式，以便为您提供最好的服务。

*公司名称：

*电子邮箱：

联系人：

*电话：

*验证码：

询价

中文别名	Butanediamide, N1-((1S,2R)-3-((((1,1-dimethylethyl)amino)carbonyl)(2-methylpropyl)amino)-2-hydroxy-1-(phenylmethyl)propyl)-2-((2-quinolinylcarbonyl)amino)-, (2S)-
英文别名	Telinavir; SC 52151; SC-52151; NSC 670881
CAS号	143224-34-4
Inchi	InChI=1S/C33H44N6O5/c1-21(2)19-39(32(44)38-33(3,4)5)20-28(40)26(17-22-11-7-6-8-12-22)36-31(43)27(18-29(34)41)37-30(42)25-16-15-23-13-9-10-14-24(23)35-25/h6-16,21,26-28,40H,17-20H2,1-5H3,(H2,34,41)(H,36,43)(H,37,42)(H,38,44)/t26-,27-,28+/m0/s1
InchiKey	ZILOOGIOHVCEKS-HZFUHODCSA-N
分子式 Formula	C33H44N6O5
分子量 Molecular Weight	604.752
溶解度Solubility
性状	Solid powder
储藏条件 Storage conditions	Dry, dark and store at 0-4℃ for short term (days to weeks) or -20℃ for long term (Store correctly 2-3years).

产品说明	Telinavir(CAS:143224-34-4):仅限应用于工业或者科学研究过程中非医疗目的，不应用于人类或动物的临床诊断以及治过程疗，该产品非药用，非食用。
Introduction	Telinavir is an anti-HIV aspartyl protease inhibitor which was in phase II clinical development with Searle (Monsanto) in the USA.
Application1
Application2
Application3

警示图
危险性	Warning
危险性警示
安全声明
安全防护
备注

[1] SC-52151, a novel inhibitor of the human immunodeficiency virus protease. M Bryant, D Getman, M Smidt, J Marr, M Clare, R Dillard, D Lansky, G DeCrescenzo, R Heintz, K Houseman, et al. Antimicrob Agents Chemother. 1995 Oct; 39(10): 2229–2234. doi: 10.1128/aac.39.10.2229 PMCID: PMC162920

[2] Recombination leads to the rapid emergence of HIV-1 dually resistant mutants under selective drug pressure.L Moutouh, J Corbeil, D D Richman Proc Natl Acad Sci U S A. 1996 Jun 11; 93(12): 6106–6111. doi: 10.1073/pnas.93.12.6106 PMCID: PMC39197

[3] Human immunodeficiency virus type 1 viral background plays a major role in development of resistance to protease inhibitors. R E Rose, Y F Gong, J A Greytok, C M Bechtold, B J Terry, B S Robinson, M Alam, R J Colonno, P F Lin Proc Natl Acad Sci U S A. 1996 Feb 20; 93(4): 1648–1653. doi: 10.1073/pnas.93.4.1648 PMCID: PMC39996

[4] A mutation in human immunodeficiency virus type 1 protease at position 88, located outside the active site, confers resistance to the hydroxyethylurea inhibitor SC-55389A. M L Smidt, K E Potts, S P Tucker, L Blystone, T R Stiebel, Jr, W C Stallings, J J McDonald, D Pillay, D D Richman, M L Bryant Antimicrob Agents Chemother. 1997 Mar; 41(3): 515–522. PMCID: PMC163743

[5] Comparison of Human Immunodeficiency Virus Type 1 Pr55Gag and Pr160Gag-Pol Processing Intermediates That Accumulate in Primary and Transformed Cells Treated with Peptidic and Nonpeptidic Protease Inhibitors R. Renae Speck, Charles Flexner, Chun-Juan Tian, Xiao-Fang Yu Antimicrob Agents Chemother. 2000 May; 44(5): 1397–1403. doi: 10.1128/aac.44.5.1397-1403.2000 PMCID: PMC89883

6: Evaluation of reverse transcriptase and protease inhibitors in two-drug combinations against human immunodeficiency virus replication. C A Deminie, C M Bechtold, D Stock, M Alam, F Djang, A H Balch, T C Chou, M Prichard, R J Colonno, P F Lin Antimicrob Agents Chemother. 1996 Jun; 40(6): 1346–1351. PMCID: PMC1633297: R88-APOBEC3Gm Inhibits the Replication of Both Drug-resistant Strains of HIV-1 and Viruses Produced From Latently Infected Cells Xiaoxia Wang, Zhujun Ao, Kallesh Danappa Jayappa, Bei Shi, Gary Kobinger, Xiaojian Yao Mol Ther Nucleic Acids. 2014 Mar; 3(3): e151. Published online 2014 Mar 4. doi: 10.1038/mtna.2014.2 PMCID: PMC40279838: Pharmacokinetics of Antiretrovirals in Mucosal Tissue M.L. Cottrell, N. Srinivas, A.D.M. KashubaExpert Opin Drug Metab Toxicol. Author manuscript; available in PMC 2016 Jun 1.Published in final edited form as: Expert Opin Drug Metab Toxicol. 2015 Jun; 11(6): 893–905. Published online 2015 Mar 22. doi: 10.1517/17425255.2015.1027682 PMCID: PMC44985669: Increasing Extracellular Protein Concentration Reduces Intracellular Antiretroviral Drug Concentration and Antiviral Effect Lindsay B. Avery, Melissa A. Zarr, Rahul P. Bakshi, Robert F. Siliciano, Craig W. Hendrix AIDS Res Hum Retroviruses. 2013 Nov; 29(11): 1434–1442. doi: 10.1089/aid.2013.0031 PMCID: PMC380960710: Genetic correlates of in vivo viral resistance to indinavir, a human immunodeficiency virus type 1 protease inhibitor. J H Condra, D J Holder, W A Schleif, O M Blahy, R M Danovich, L J Gabryelski, D J Graham, D Laird, J C Quintero, A Rhodes, H L Robbins, E Roth, M Shivaprakash, T Yang, J A Chodakewitz, P J Deutsch, R Y Leavitt, F E Massari, J W Mellors, K E Squires, R T Steigbigel, H Teppler, E A Emini J Virol. 1996 Dec; 70(12): 8270–8276. PMCID: PMC190914

对不起，暂无产品评价！

MSDS

SDS 1.0 中文

展开

SDS 1.0 英文

展开